28L.F PEPTONIC MEDICAL
- Market cap
- EUR 5.52M
- P/E
- -
- P/B
- 1.17x
- ROE
- -36.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 28L.F undervalued?
Graham numberThe Graham number of PEPTONIC MEDICAL cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PEPTONIC MEDICAL fundamental analysis
No fundamental analysis for PEPTONIC MEDICAL yet.
PEPTONIC MEDICAL stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PEPTONIC MEDICAL
PEPTONIC medical AB (publ), a medical technology company, develops and sells intimate self-care products for women. The company offers products under the VagiVital brand, including a moisturizing gel for atrophy; an intimate calming gel for rapid relief of itching and irritation; moisturizing lubricant; a pH-balancing intimate wash/conditioner; self-test kits for diagnosing pre-menopause, menopause, vaginal infection, bacterial vaginosis, and amniotic fluid leakage; and gene…
Full company profilePEPTONIC MEDICAL financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PEPTONIC MEDICAL annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 31.6M | 43.6M | 37.1M | 26.9M | 14.8M | 11.0M |
| Gross Profit | 19.1M | 23.4M | 16.3M | 15.2M | 9.95M | 7.07M |
| Operating Income | -73.7M | -33.6M | -41.2M | -40.6M | -19.4M | -18.1M |
| EBITDA | - | -27.8M | -34.0M | -51.9M | -13.6M | -12.1M |
| Net Income | -73.7M | -36.9M | -42.6M | -60.0M | -22.5M | -19.0M |
| EPS | -0.15 | -0.06 | -0.02 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | ||||||
| Total Assets | 84.6M | 85.8M | 107M | 70.6M | 65.9M | 59.8M |
| Total Liabilities | 31.5M | 38.7M | 31.4M | 22.0M | 27.7M | 7.79M |
| Shareholders' Equity | 53.1M | 47.1M | 75.3M | 48.6M | 38.2M | 52.1M |
| Cash & Short-term Investments | 10.2M | 3.57M | 15.1M | 3.74M | 195K | 758K |
| Cash Flow | ||||||
| Operating Cash Flow | -40.3M | -40.2M | -33.8M | -37.6M | -20.5M | -4.42M |
| Capital Expenditure | 4.28M | 987K | 1.93M | 1.20M | 162K | 186K |
| Free Cash Flow | -44.6M | -41.2M | -35.7M | -38.8M | -20.7M | -4.60M |
| Ratios | ||||||
| ROE | -138.7% | -78.3% | -56.5% | -123.6% | -58.8% | -36.6% |
| ROA | -87.1% | -43.0% | -39.9% | -85.1% | -34.1% | -31.8% |
| Net Profit Margin | -232.9% | -84.5% | -114.7% | -223.2% | -152.1% | -173.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PEPTONIC MEDICAL dividends
PEPTONIC MEDICAL has not paid dividends in the last 6 fiscal years.
Who owns PEPTONIC MEDICAL
- Insiders 13.64%
- Institutions 3.74%
- Public & others 82.62%
- Shares outstanding 27.6B
- Free float 26.5B
PEPTONIC MEDICAL company profile
- Company name
- PEPTONIC MEDICAL
- Ticker
- 28L.F
- ISIN
- SE0005962206
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2
- Fiscal year end
- December
- Address
- Färögatan 33, Kista, Sweden, 164 53
- Phone
- 46 8 53 02 01 10
- Website
- peptonicmedical.se
About PEPTONIC MEDICAL
PEPTONIC medical AB (publ), a medical technology company, develops and sells intimate self-care products for women. The company offers products under the VagiVital brand, including a moisturizing gel for atrophy; an intimate calming gel for rapid relief of itching and irritation; moisturizing lubricant; a pH-balancing intimate wash/conditioner; self-test kits for diagnosing pre-menopause, menopause, vaginal infection, bacterial vaginosis, and amniotic fluid leakage; and gene test for diagnosing vaginal infection. It also provides VerniVia mousse, a product against bacterial vaginosis; VagiVital AktivGel, a treatment of vaginal atrophy and vaginal dryness; VagiVital calming gel for relief from irritation and itching in the outer intimate area; VagiVital Moisturizing V Cleanser; and VagiVital, a Moisturizing V Cleanser. It sells products through pharmacies, digitally, and physical stores. PEPTONIC medical AB (publ) was incorporated in 2009 and is headquartered in Kista, Sweden.
PEPTONIC MEDICAL management
2- Mr. Daniel RudeklintInterim CEO & Director · born 1981
- Ms. Jenni BjornulfsonChief Financial Officer · born 1971